G 4660

Drug Profile

G 4660

Alternative Names: UIF 100

Latest Information Update: 28 Sep 2006

Price : $50

At a glance

  • Originator The Solae Company
  • Developer National Cancer Institute (USA)
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Sep 2006 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 07 Nov 2003 Protein Technologies International is now called The Solae Company
  • 05 Sep 2001 Phase-I clinical trials for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top